Literature DB >> 30448333

Sero-prevalence of rubella among pregnant women in India, 2017.

Divya Elizabeth Muliyil1, Pratibha Singh2, Srinivas Krishna Jois3, Suhas Otiv4, Vanita Suri5, Vishakha Varma6, Asha Mary Abraham1, Chandrakant Raut7, Minakshi Gupta6, Mini P Singh5, Rajalakshmi Viswanathan8, Sadanand Naik4, Vijaylakshmi Nag2, Asha Benakappa9, Ashish Bavdekar4, Gajanan Sapkal8, Kuldeep Singh2, Nivedita Gupta10, Sanjay Verma5, Sridhar Santhanam1, Sudhir Mishra6, Ambar Bhatnagar2, G R V Prasad5, Jyoti Kolekar4, Naga Raj11, R Sabarinathan11, Ravinder Kaur Sachdeva5, Suji George8, Shyama Chaudhary2, Valsan Philip Verghese1, Vishal Jagtap8, Manasa Bharadwaj9, Manoj Murhekar12.   

Abstract

BACKGROUND: We conducted a sero-survey among pregnant women attending antenatal clinics of six hospitals which also function as sentinel sites for CRS surveillance, to estimate the prevalence of IgG antibodies against rubella.
METHODS: We systematically sampled 1800 pregnant women attending antenatal clinics and tested their sera for IgG antibodies against rubella. We classified sera as seropositive (titre ≥10 IU/ml), sero-negative (titre <8 IU/ml) or indeterminate (titre 8-9.9 IU/ml) per manufacturer's instructions. In a sub-sample, we estimated the titers of IgG antibodies against rubella. IgG titer of ≥10 IU/mL was considered protective.
RESULTS: Of 1800 sera tested, 1502 (83.4%) were seropositive and 24 (1.3%) were indeterminate and 274 (15.2%) were sero-negative. Rubella sero-positivity did not differ by age group, educational status or place of residence. Three hundred and eighty three (87.8%) of the 436 sera had IgG concentrations ≥10 IU/mL.
CONCLUSION: The results of the serosurvey indicate high levels of rubella sero-positivity in pregnant women. High sero-prevalence in the absence of routine childhood immunization indicates continued transmission of rubella virus in cities where sentinel sites are located.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  India; Rubella virus; Sero-prevalence

Mesh:

Substances:

Year:  2018        PMID: 30448333     DOI: 10.1016/j.vaccine.2018.11.013

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Epidemiology of Congenital Rubella Syndrome (CRS) in India, 2016-18, based on data from sentinel surveillance.

Authors:  Manoj Murhekar; Sanjay Verma; Kuldeep Singh; Ashish Bavdekar; Naveen Benakappa; Sridhar Santhanam; Gajanan Sapkal; Rajlakshmi Viswanathan; Mini P Singh; Vijaya Lakshmi Nag; Sadanand Naik; Munivenkatappa Ashok; Asha Mary Abraham; Devika Shanmugasundaram; R Sabarinathan; Valsan Philip Verghese; Suji George; Ravinder Kaur Sachdeva; Jyoti Kolekar; S Manasa; Jagat Ram; Madhu Gupta; Manoj K Rohit; Praveen Kumar; Parul Chawla Gupta; R K Ratho; Sanjay Kumar Munjal; Urvashi Nehra; Daisy Khera; Neeraj Gupta; Nidhi Kaushal; Pratibha Singh; Ravisekhar Gadepalli; Neelam Vaid; Sandeep Kadam; Sanjay Shah; S Mahantesh; Vykuntaraju K Gowda; Pradeep Haldar; M K Aggarwal; Nivedita Gupta
Journal:  PLoS Negl Trop Dis       Date:  2020-02-03

2.  Cost of conducting Measles-Rubella vaccination campaign in India.

Authors:  Susmita Chatterjee; Dayoung Song; Palash Das; Pradeep Haldar; Arindam Ray; Logan Brenzel; Laura Boonstoppel; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2021-08-19       Impact factor: 3.452

3.  The Screening of Rubella Virus, Cytomegalovirus, Hepatitis B Virus, and Toxoplasma gondii Antibodies in Prepregnancy and Reproductive-Age Women in Tabriz, Iran.

Authors:  Edris Nabizadeh; Anahita Ghotaslou; Behnaz Salahi; Reza Ghotaslou
Journal:  Infect Dis Obstet Gynecol       Date:  2022-01-10

4.  Seroprevalence and Determinants of ToRCH Pathogens in Pregnant Women in the Sub-Himalayan Region.

Authors:  Sangeeta Deka; Deepjyoti Kalita; Manisha Paul; Gaurav Badoni; Yogendra P Mathuria
Journal:  Cureus       Date:  2022-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.